Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 6/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.42 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15716079 | 0.85 | KIF11 (0.49) | RXRAGRIN1GRIN2BIDO1PDK2 | |
| SCHEMBL19251077 | 0.82 | PTPN7 (0.44) | RXRAGRIN1GRIN2BPTPN7DUSP3 | |
| SCHEMBL25735770 | 0.81 | IDO1 (0.45) | IDO1PDK2PTPN1 | |
| SCHEMBL1716084 | 0.81 | IDO1 (0.67) | PTPN7DUSP3IDO1 | |
| SCHEMBL12509484 | 0.81 | SLC6A4 (0.50) | RXRAGRIN1GRIN2BPTPN7DUSP3 | |
| SCHEMBL25735783 | 0.80 | S1PR1 (0.45) | PTPN7DUSP3IDO1ARPDK2 | |
| Hydrochloric Acid SCHEMBL1715172 | 0.80 | IDO1 (0.68) | IDO1 | |
| SCHEMBL3156462 | 0.79 | PTPN7 (0.43) | RXRAGRIN1GRIN2BPTPN7DUSP3 | |
| SCHEMBL5023454 | 0.79 | AR (0.48) | RXRAGRIN1GRIN2BPTPN7DUSP3 | |
| SCHEMBL10299806 | 0.79 | AR (0.48) | RXRAGRIN1GRIN2BPTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | RXRA 1649/4885GRIN1 3521/4885GRIN2B 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.